Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Add On Therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    575 result(s) found for: Add On Therapy. Displaying page 1 of 29.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-000739-97 Sponsor Protocol Number: HIC Start Date*: 2011-05-05
    Sponsor Name:Med. Univ. Wien
    Full Title: Prospective, randomized, controlled, open-label study evaluating quality of life in patients with advanced malignant tumors with and without “add-on” homeopathy
    Medical condition: Homeopathic remedies as add on therapie in cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000815-15 Sponsor Protocol Number: HLS14/01 Start Date*: 2015-07-22
    Sponsor Name:Azienda Ospedaliera, Polo Universitario Luigi Sacco, Milano
    Full Title: Effects of a late add-on therapy of pegylated interferon (peg-IFNA) to ongoing nucleos(t)ide analogs (NUCs) in patients with chronic hepatitis B (CHB).
    Medical condition: Chronic hepatitis B
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001143-46 Sponsor Protocol Number: CLAF237ADE08 Start Date*: 2012-07-10
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized open-label study to compare safety and efficacy of vildagliptin versus NPH insulin add-on to glimepiride in patients with type 2 diabetes mellitus that do not reach adequate glycemic c...
    Medical condition: type-2 diabetes mellitus that do not reach adequate glycemic control on their current sulfonylurea monotherapy
    Disease: Version SOC Term Classification Code Term Level
    15.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000542-20 Sponsor Protocol Number: CLAF237A2338 Start Date*: 2004-07-16
    Sponsor Name:NOVARTIS FARMA
    Full Title: A Multicenter, Double-Blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily as Add-On Therapy in Patients wit...
    Medical condition: treatment of type 2 diabetes in combination therapy with other anti-diabetic oral drugs
    Disease: Version SOC Term Classification Code Term Level
    6.1 10018424 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SK (Completed) ES (Completed) DK (Completed) CZ (Completed) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001546-32 Sponsor Protocol Number: CLAF237A2305 Start Date*: 2004-09-07
    Sponsor Name:Novartis Finland Oy
    Full Title: A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF237 (50 mg qd or bid) to placebo as add-on therapy to glimepiride in patients with ...
    Medical condition: Patients with type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) LT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-003235-31 Sponsor Protocol Number: Prof. Franz Weidinger Start Date*: 2005-01-31
    Sponsor Name:Div. of Cardiology, Innsbruck Medical University
    Full Title: Effect of pravastatin or fluvastatin and add-on valsartan on inflammatory markers and peripheral endothelial function in patients with acute coronary syndrome
    Medical condition: Acute coronary syndrome; patients with NSTEMI
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004559-21 Sponsor Protocol Number: CLAF237A2308 Start Date*: 2005-03-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Long-Term Effect (up to 5 Years) of Treatment with LAF237 50 mg bid to Glimepiride up to 6 mg Daily as Add-On Therapy...
    Medical condition: Type II Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Prematurely Ended) GB (Completed) LT (Completed) EE (Completed) LV (Completed) IT (Prematurely Ended) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-001989-42 Sponsor Protocol Number: TEA-Stroke Start Date*: 2013-08-02
    Sponsor Name:Boris Modrau
    Full Title: Theophylline Effect in Acute Ischemic Stroke Trial
    Medical condition: Acute ischemic stroke patients eligible for standard intravenous recombinant tissue plasminogen activator (rtPA) thrombolytic therapy with magnet resonance imaging (MRI)-proved infarction
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10023027 Ischaemic stroke NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015979-27 Sponsor Protocol Number: TRX2 Start Date*: 2010-02-25
    Sponsor Name:Activartis Biotech GmbH
    Full Title: First line standard therapy of glioblastoma multiforme with or without add-on treatment with Trivax, an anti-tumour immune therapy based on tumour-lysate charged dendritic cells
    Medical condition: Patients older than 3 years of age with newly diagnosed Glioblastoma Multiforme (GBM) undergoing brain surgery for removal of at least 70% of tumour mass and receiving subsequently standard radiati...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021097-11 Sponsor Protocol Number: CLAF237A23152 Start Date*: 2010-11-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind placebo controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin 50 mg bid as add-on therapy to metformin plus glimepiri...
    Medical condition: Type II Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003127-38 Sponsor Protocol Number: NL71001.029.19 Start Date*: 2020-04-09
    Sponsor Name:VUmc Neurology Department
    Full Title: Efficacy of add-on high dose simvastatin on markers for disease progression in MS patients treated with ocrelizumab and natalizumab (SIMSON), a phase II clinical trial.
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001664-38 Sponsor Protocol Number: FFA-MAE Start Date*: 2019-10-02
    Sponsor Name:University Hospital Schleswig-Holstein (UKSH)
    Full Title: A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome)
    Medical condition: Childhood epilepsy: Myoclonic Astatic Epilepsy (Doose-Syndrome)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10015040 Epilepsy equivalent LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2016-004059-53 Sponsor Protocol Number: 16-OBE2109-009 Start Date*: 2017-05-25
    Sponsor Name:ObsEva SA
    Full Title: A Phase 3, multicentre, randomized, double-blind, placebo controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add-back thera...
    Medical condition: Treatment of heavy menstrual bleeding associated with uterine fibroids.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000021126 10046784 Uterine fibroids LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) LV (Completed) CZ (Completed) BG (Completed) PL (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018580-42 Sponsor Protocol Number: PXL008-002 Start Date*: 2010-06-11
    Sponsor Name:Poxel
    Full Title: Randomized, double-blind, placebo-controlled, parallel-group study of the safety and efficacy of imeglimin or placebo add-on therapy in type 2 diabetic subjects not adequately controlled by metform...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012607 Diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-000541-12 Sponsor Protocol Number: AC-058B302 Start Date*: 2016-11-15
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: Multicenter, randomized, double-blind, parallel-group, add-on, superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who ...
    Medical condition: Relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PT (Completed) DK (Completed) HU (Completed) CZ (Completed) AT (Completed) ES (Prematurely Ended) GR (Completed) BG (Completed) FR (Completed) PL (Completed) FI (Completed) BE (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002812-10 Sponsor Protocol Number: PADD-ON Start Date*: 2012-01-03
    Sponsor Name:University Medical Center of the Johannes Gutenberg University Mainz
    Full Title: A prospective, randomised, open-label phase IIb clinical trial assessing the effect of pegylated Interferon alfa-2a (Pegasys®) 180 µg once weekly for 48 weeks in addition to an ongoing nucelos(t)id...
    Medical condition: Patients with chronic HBeAg-negative hepatitis B with a stable oral antiviral treatment (not containing telbivudine) and a fully suppressed viral load for at least 12 months (below limit of detecti...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000109834 10019738 Hepatitis B positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001099-11 Sponsor Protocol Number: CIGE025A2425 Start Date*: 2005-10-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open label, parallel-group, international, multicenter study evaluating persistency of response to omalizumab during 32 weeks treatment given as add on to optimized asthma therapy in ...
    Medical condition: Severe persistent allergic asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001705 Allergic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NO (Completed) IE (Completed) ES (Completed) DK (Completed) SE (Completed) DE (Completed) HU (Completed) PT (Not Authorised) IT (Completed) BE (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006239-11 Sponsor Protocol Number: HBV 09-01 Start Date*: 2009-05-15
    Sponsor Name:Stichting Lever Onderzoek
    Full Title: Augmenting response to entecavir using a temporary peginterferon alpha-2a add-on strategy for the treatment of HBeAg-positive chronic hepatitis B (ARES study)
    Medical condition: Chronic hepatitis B virus infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008910 Chronic hepatitis B LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003813-92 Sponsor Protocol Number: EPT02/2016 Start Date*: 2017-01-25
    Sponsor Name:IBSA FARMACEUTICI ITALIA SRL
    Full Title: Open clinical trial to evaluate the efficacy of intravesical instillation of hyaluronate added to early instillation of mitomycin vs early instillation of mitomycin in patients suffering from low r...
    Medical condition: Low risk not muscle-infiltrating bladder neoplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004253-22 Sponsor Protocol Number: ALXN2040-PNH-303 Start Date*: 2022-07-04
    Sponsor Name:Alexion Pharmaceuticals Inc.
    Full Title: A Long-term Extension (LTE) Study to Characterize the Safety and Efficacy of Danicopan as an Add-on Therapy to a Complement Component 5 Inhibitor (C5i) in Patients with Paroxysmal Nocturnal Hemoglo...
    Medical condition: Patients with Paroxysmal Nocturnal Hemoglobinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10034042 Paroxysmal nocturnal haemoglobinuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Ongoing) GR (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:20:47 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA